Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine

Journal of Viral Hepatitis

Volumn 9, Issue 1, 2002, Pages 75-79

  Pérez Álvarez, Ramón ^a   Perez Lopez R ^a   Lombrana J L S ^a   Rodriguez M ^a   Rodrigo, L ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Amantadine; Hepatitis C; Interferon; Ribavirin; Sarcoidosis

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; AMINOTRANSFERASE; CORTICOSTEROID; PARACETAMOL; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FEVER; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; CASE REPORT; DRUG SYNERGISM; FEMALE; HEPATITIS C, CHRONIC; HUMAN; INTERFERON ALFA-2A; LUNG DISEASES; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RIBAVIRIN; SARCOIDOSIS;

EID: 0036905295     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00105.x     Document Type: Article

References (37)

1. Robinson BW, McLemore TL, Crystal BG. Gamma interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. N J Clin Invest 1985; 75: 1488-1495.
2. Pietropaoli A, Modrak J, Utell M. Interferon-α therapy associated with the development of sarcoidosis. Chest 1999; 116: 569-572.
3. Hoffmann RM, Jung M-Ch, Motz R et al. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C. J Hepatol 1998; 28: 1058-1063.
4. Cacoub P, Sbaï A, Francés C, Génesti C, Hausfater P, Piette JC. Sarcoï systémique au cors dún traitment par interféron alpha pour une hépatite chronique virale C. Gastroenterol Clin Biol 2000; 24: 364-366.
5. Fiorani C, Sacchi S, Bonacorsi G, Cosenza M. Systemic sarcoidosis associated with interferon-α treatment for chronic myelogenous leukemia. Haematologica 2000; 85: 1006-1007.
6. Vander Els NJ, Gerdes H. Sarcoidosis and IFN-α treatment (letter). Chest 2000; 117: 294.
7. Amaya M, Shijubo N, Fujii N, Oguma K, Abe S. Oligo-2′,5′-adenylate synthetase in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 1994; 105: 496-500.
8. Kubo K, Yamaguchi S, Fujimoto K et al. Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection. Thorax 1996; 51: 312-314.
9. Yamaguchi S, Kubo K, Fujimoto K, Honda T, Sekiguchi M, Sodeyama T. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha. Thorax 1997; 52: 33-37.
10. Ueda T, Ohta K, Suzuki M et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992; 146: 266-268.
11. Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax 1996; 51: 315-317.
12. Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral induced macrophage production of tumour necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response (Abstract). Hepatology 1996; 24: 355.
13. Fang S-H, Hwang L-H, Chen D-S, Chiang B-L. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33: 791-798.
14. Gomez V, Smith PR, Burack J, Daley R, Rosa U. Sarcoidosis after antiretroviral therapy in a patient with adquired immunodeficiciency syndrome. Clin Infect Dis 2000; 31: 1278-1280.
15. Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Braukner MW. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. Am J Roentgenol 2000; 174: 1751-1757.
16. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. The six phases of treatment. Chest 1999; 115: 1158-1165.
17. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
18. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Resp Crit Care Med 1999; 160: 192-197.
19. Luers C, Sudhop T, Spengler U, Berthold HK. Improvement of sarcoidosis under therapy with interferon-α 2b for chronic hepatitis B virus infection (letter). J Hepatol 1999; 30: 347.
20. Kamisako T, Chihara YA, Yamamoto T. Interstitial pneumonitis and interferon-alfa. Br Med J 1993; 306: 896.
21. Moriya K, Yasuda K, Koike K et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994; 29: 514-517.
22. Pallavicini EB, Valsecchi C, Tacconi F, Moroni M, Porta C. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12: 140.
23. Drosos AA, Voulgary PV, Psychos DN, Tsifetaki N, Bai M. Sicca syndrome in patients with sarcoidosis. Rheumatol Int 1999; 18: 177-180.
24. Khan AH, Ghani F, Khan A, Khan MA, Khursid M. Role of serum angiotensin converting enzyme in sarcoidosis. J Pak Med Assoc 1998; 48: 131-133.
25. Wilson NJ, King CM. Cutaneous sarcoidosis. Postgrad Med J 1998; 74: 649-652.
26. Okamoto H. Epidermal changes in cutaneous lesions of sarcoidosis. Am J Dermatopathol 1999; 21: 229-233.
27. Belgodere X, Viraben R, Gorguet B, Allaouchiche B, Lieutaud O, Maestracci D. Guess what! Cutaneous sarcoidosis, Sjögren's syndrome and autoimmune thyroiditis associated with hepatitis C virus infection. Eur J Dermatol 1999; 9: 235-236.
28. Ohhata I, Ochi T, Kurebayashi S, Matusani H, Kikui M. A case of subcutaneous sarcoid nodules induced by interferon-alpha. Nippon Kyobu Shikkan Gakkai Zasshi 1994; 32: 996-1000.
29. Savoye G, Goria O, Herve S et al. Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C. Gastroenterol Clin Biol 2000; 24: 679.
30. Koffman B, Junck L, Elias SB, Feit HW, Levine SR. Polyradiculopathy in sarcoidosis. Muscle Nerve 1999; 22: 608-613.
31. Arias M, Requena I, Lema C, Navarro C. Subacute polyneuropathy as the initial manifestation of sarcoidosis (letter). Neurología 2000; 15: 88-89.
32. Ferri C, La Civita L, Fazzi P, Pasero G, Zignego AL. Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. Arthritis Rheumatol 1996; 39: 1074-1075.
33. Weidensaul D, Imam T, Holyst M-M, King PD, McMurray RW. Polymyositis, pulmonary fibrosis and hepatitis C. Arthritis Rheumatol 1995; 38: 437-439.
34. Berner B, Schulz E, Wieneke U, Reuss-Borst MA, Sattler B, Muller GA. Rapidly progressing renal insufficiency as the primary manifestation of systemic sarcoidosis. Med Klin 1999; 94: 690-694.
35. Wong VS, Adab N, Youngs GR, Sturgess R. Hepatic sarcoidosis complicated by hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999; 11: 353-355.
36. Zeuzem S, Teuber G, Naumann U et al. Randomized double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835-841.
37. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-634.